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The past several decades have produced remarkable techno-
logical and therapeutic innovations in the prevention and
treatment of cardiovascular disease, resulting in impressive
reductions in cardiovascular-related morbidity and mortality
(1,2). These enhanced clinical outcomes coincide with a
time of significant stress within our health care system,
namely, with the burden of ballooning costs of care. In
recent years, health care spending has grown much faster
than the rate of inflation, with cardiovascular expendi-
tures accounting for the largest portion of spending (3,4).
See page 1817
At these growth rates, expenditures related to cardiovascular
disease are estimated to triple over the next 20 years, approach-
ing $1 trillion by 2030 (2). The challenge for health system
eform is to enable continued improvements in care while
ontaining the growth in expenditures.
In this issue of the Journal, Choudhry et al. (5) report on
he clinical and economic implications of an intervention by
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he clinical benefit—not the price—of essential medica-
ions. Cost shifting to consumers in the form of increased
remiums, and cost sharing at the point of service, is a
ommon and effective technique to control health care
xpenditures. The theoretical basis for cost sharing in the
orm of copayments and deductibles is to involve consumers
n the decision making around care choices, particularly
hen considering the use of low-value or unproven services
6,7). By assuming a portion of the cost, patients have some
esponsibility regarding the selection of services that are of
ost value to them on the basis of their preferences and
edical needs.
A major limitation of typical cost-sharing arrangements
n most private and public health plans in the United States
s that patients’ copayments are typically set at the same
rice for a certain type of service (e.g., physician visit,
ospital stay, drug within a formulary tier) regardless of the
elative clinical value of specific interventions within each
ype of service. In such a “one-size-fits-all” system, there is
o inherent consideration of the evidence-based effective-
ess of an intervention. Published research clearly shows
hat as copayments have increased for all services, regardless
f their clinical value, decreased utilization has resulted for
ssential screening, clinician visits, and treatments, often
eading to worse outcomes and in some cases higher
ggregate expenditures (6,8–14).
Cost-containment efforts should not produce preventable
ecreases in the quality of care. Thus, value-based insurance
esign (V-BID) was developed to mitigate the negative
linical consequences of one-size-fits-all models of patient
ost sharing. The basic premise of V-BID is to remove
arriers to essential, high-value health services. Using a “clin-
cally nuanced” approach, patients assume an out-of-pocket
ost proportional to the clinical value—not the price—of a
iven service (15). V-BID incorporates available evidence
egarding the clinical benefit for a given intervention and can
e tailored for application to a specific patient or group (16).
This evidence-based approach to patient cost sharing is
nnovative in its ability to make highly effective care more
ttractive by reducing or eliminating patient barriers. Con-
ersely, increasing patient cost sharing can make poorly
ffective, lower value care less desirable. By promoting the
ost effective cardiovascular interventions, V-BID pro-
rams act to increase the quality of care received by patients
nd add efficiency to the system as a whole.
Choudhry et al. (5) evaluated a V-BID program that
educed patient cost sharing for average-risk patients pre-
cribed statins and clopidogrel. Lower patient out-of-
ockets costs were associated with improvements in patient
edication adherence, with cost neutrality in overall health
are spending. Rates of physician office visits, emergency
epartment admissions, and hospitalizations were lower
mong patients with lower copayments for statins and
lopidogrel. These findings were similar to those reported
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Infarction Free Rx Event and Economic Evaluation) study,
a randomized trial in which elimination of cost sharing for
guideline-recommended drugs for patients after myocardial
infarction was compared with conventional cost-sharing
arrangements (17). In that study, patients randomized to
elimination of out-of-pocket costs for high-value, evidence-
based cardiovascular medicines showed significant reduc-
tions in several important secondary outcomes, including
reductions in the rates of first major vascular events, total
major vascular events, and revascularization. Notably, the
results of both studies by Choudhry et al. (5) were achieved
without increasing total health care costs.
It is important to note that V-BID programs never dictate
what services are to be included or excluded from coverage by
payers. Clinically nuanced designs merely reset copayments on
the basis of clinical benefit instead of purchase price. Available
evidence suggests that variable cost-sharing structures will
decrease cost-related nonadherence of high-value services. By
avoiding absolute “covered or not” decisions, V-BID may
reduce unnecessary conflict or perception of conflict among
providers, payers, and patients; in so doing, it can protect the
integrity of the physician-patient relationship in forming
patient-centered tailored plans of care.
V-BID is distinct from, yet complementary to, many
other health reform proposals. Popular initiatives that target
health systems and clinicians, such as global payment
systems, accountable care organizations, patient-centered
medical homes, and value-based purchasing programs, shift
financial risks and incentives for quality and efficiency to
health systems and providers. These “supply-side” strategies
often do not explicitly address consumer incentives, the
“demand side” of this complex system. Alignment of clinical
and financial aims for providers and patients, rather than just
providers, will likely lead to faster achievement of program goals.
Cardiovascular medicine is well suited for V-BID imple-
mentation, because clinically nuanced programs perform
best when there is high-quality evidence and/or consensus
regarding the benefits of care. There are potential V-BID
applications along the entire continuum of cardiovascular
care, from primary prevention and risk factor management
to diagnosis and medical management of cardiovascular
disease, through resource-intensive interventions. In fact,
several large public and private organizations have already
successfully applied V-BID programs. Aetna, the nation’s
fourth largest health insurance company, has used a copay-
ment relief program for patients with histories of heart
disease. Other public and private organizations that have
implemented V-BID include the city of Asheville, North
Carolina, the states of Oregon and Maine, Pitney Bowes,
the Marriott Corporation, United Healthcare, and several
labor groups. The Mercer National Survey of Employer-
Sponsored Health Plans reports that value-based insurance
design use is increasing and that 81% of large employers
plan to offer it in the near future (18). In these applications,
V-BID has improved quality measures, including medica-tion adherence rates, hospitalizations, and disability days in
a potentially cost-saving manner (19–21). Encouraged by
the success of private-sector implementation, V-BID was
explicitly included in the Patient Protection and Affordable
Care Act (§ 2713[c]). V-BID has also been highlighted in
the Institute of Medicine’s report Essential Health Benefits:
Balancing Coverage and Cost (22) and in the 2012 Medi-
care Payment Advisory Committee (23) report to Congress,
in which V-BID was promoted as a potential direction for
Medicare benefit redesign.
Many health reform proposals that focus primarily on
cost containment will be directed by nonclinicians, who may
have a limited understanding regarding quality of care.
Thus, to ensure that patient-centered outcomes remain a
critical policy priority, cardiologists will be required to have
a facile understanding of the quality and value of their
services and be adept at communicating that value to policy
makers and health care administrators. Novel approaches
that embed clinical nuance in payment and benefit designs
have the advantage of inherently directing care toward
efficient and effective interventions without requiring undue
physician administrative efforts or internecine budgetary
conflicts among providers. V-BID is an intuitive, feasible
concept that could be applied to address the well-
documented underuse of lifesaving clinical services for the
diagnosis, prevention, and treatment of cardiovascular dis-
ease. Choudhry et al. (5) demonstrate that incentivizing
evidence-based medication use can lead to tangible clinical
benefits without increasing costs. Similarly, V-BID princi-
ples can go beyond medications to incentivize high-value
procedure use, such as implantable cardioverter-defibrillators
for patients with ejection fractions 35% and medically
optimized New York Heart Association class II or III heart
failure, as well as percutaneous coronary intervention in
patients with Canadian Cardiovascular Society class III or
IV angina despite maximal antianginal therapy. Although
increasing utilization of these services would increase short-
term health care expenditures, future cost offsets occur when
costly complications are avoided or when the utilization of
low-value service can be reduced.
Health care reform strategies that simultaneously address
quality improvement and cost containment have the potential
to increase the amount of health achieved for the money spent.
Cardiologists can shape reform efforts by clearly defining
high-value and low-value cardiovascular services and embrac-
ing innovative payment reform and benefit designs that will
better enable the provision of patient-centered, evidence-based
care.
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